Imedex: Education is the Best Medicine®

QUICK POLL

Alcohol consumption is known to increase a woman’s risk of developing breast cancer. For women who have already been diagnosed with breast cancer, how many drinks per week increase the risk for recurrence of their breast cancer?

Great Debates and Updates in Hematologic Malignancies

April 30 - May 1, 2010

New York, New York, USA

Westin New York Times Square

Continuing Medical Education

Imedex, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
This activity has been approved for 12.5 of AMA PRA Category 1 Credit^TM.

Who Should Attend
This educational activity is primarily targeted to academic and community hematologists and oncologists, and secondarily to oncology nurses and other health care professionals interested in the management of patients with hematologic malignancies.

Objectives
After successful completion of this course, attendees should be able to:

Identify the most effective therapeuticstrategies and novel combinations for acute leukemias, especially for the care of
elderly patients
Correctly utilize imaging techniques to ensure successful management and validate response criteria for patients with
non-Hodgkin’s lymphoma
Review traditional treatment strategies for lymphoma and decide whether emerging, updated therapies could potentially
optimize patient outcomes
Determine how the emergence of novel agents in multiple myeloma could affect the use of markers for patient risk
stratification and approaches to overcome treatment resistance
Evaluate the optimal frontline approach to multiple myeloma treatment, including the most favorable number of agents,
treatment sequencing, inclusion of novel agents, and the use of bisphosphonates for symptom management
Determine how to effectively manage multiple myeloma patients with preexisting complications

Asher A. Chanan-Khan, MD
Roswell Park Cancer Institute
Buffalo, New York

Morton Coleman, MD, FACP
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Jorge E. Cortes, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Harold P. Erba, MD, PhD
University of Michigan Medical Center
Ann Arbor, Michigan

Rafael Fonseca, MD
Mayo Clinic
Scottsdale, Arizona

Guillermao Garcia-Manero, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Hagop M. Kantarjian, MD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Shaji Kumar, MD
Mayo Clinic
Rochester, Minnesota

John P. Leonard, MD
Center for Lymphoma and Myeloma
Weill Medical College of Cornell University
The New York-Presbyterian Hospitals
New York, New York

Sagar Lonial, MD
Emory University Winship Cancer Institute
Atlanta, Georgia

Peter Martin, MD
Weill Cornell Medical College
New York, New York

Ruben A. Mesa, MD
Mayo Clinic
Rochester, Minnesota

Craig Moskowitz, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Stephen Nimer, MD
Memorial Sloan-Kettering Cancer Center
New York, New York

Susan O’Brien, MD
University of Texas
M. D. Anderson Cancer Center
Houston, Texas

Owen A. O’Connor, MD, PhD
Columbia University
Herbert Irving Comprehensive
Cancer Center
New York, New York

Robert Z. Orlowski, MD, PhD
The University of Texas
M. D. Anderson Cancer Center
Houston, Texas

S. Vincent Rajkumar, MD
Mayo Clinic
Rochester, Minnesota

Paul G. Richardson, MD
Dana-Farber Cancer Institute
Harvard Medical School
Boston, Massachusetts

Gail J. Roboz, MD
Weill Cornell Medical College
New York, New York

Gary Schiller, MD, FACP
University of California Los Angeles
Los Angeles, California

Richard T. Silver, MD
Weill Cornell Medical College
New York, New York

Steven P. Treon, MD, PhD
Dana-Farber Cancer Institute
Boston, Massachusetts

Andrew D. Zelenetz, MD, PhD
Memorial Sloan-Kettering Cancer Center
New York, New York

ENDORSED BY

Friday, April 30, 2010

8:00 am
Introduction

8:10 am
Acute Leukemia Session
Debate: Is chemotherapy still useful for APL in the era of ATRA
and arsenic trioxide?
Harold P. Erba, MD, PhD
Gary Schiller, MD

8:35 am
Debate: What is the most appropriate and effective therapy for elderly AML patients?
Gary Schiller, MD, FACP
Harold P. Erba, MD, PhD

9:00 am
Emerging novel and promising therapeutic agents for AML
Stephen Nimer, MD

9:25 am
Coffee break

9:45 am
Lymphoma Session I
Debate: Should the results of interim PET scans change the planned management of advanced hodgkins lymphoma or diffuse large
B-cell lymphoma?
Morton Coleman, MD, FACP
Craig Moskowitz, MD

10:10 am
Debate: Should surveillance CT scans be performed on DLBC lymphoma patients who achieve a CR from frontline therapy?
Andrew D. Zelenetz, MD, PhD
Peter Martin, MD

10:35 am
Debate: What is the most appropriate second line therapy for advanced follicular lymphoma patients who relapse following frontline R-CHOP?
Craig Moskowitz, MD
Andrew D. Zelenetz, MD, PhD
John P. Leonard, MD

11:05 am
What is the most appropriate management for stage I follicular lymphoma in a young patient - deciding when and with what to initiate therapy?
John P. Leonard, MD

11:35 am
Lunch

12:40 pm
Myeloma Session I
Debate: Since novel agents appear to abrogate the negative impact of poor risk cytogenetics, are cytogenetics by FISH still a necessary part of risk stratification for newly diagnosed multiple myeloma patients?
Sagar Lonial, MD
S. Vincent Rajkumar, MD

1:05 pm
Debate: What is the most appropriate frontline regimen for transplant ineligible myeloma patients?
Steven P. Treon, MD, PhD
Sagar Lonial, MD
S. Vincent Rajkumar, MD

1:30 pm
Debate: How should bisphosphonates be utilized in multiple myeloma patients responding to frontline therapy?
Speaker invited
Robert Z. Orlowski, MD, PhD

1:55 pm
Debate: For newly diagnosed SCTeligible myeloma patients the most appropriate induction therapy is:
Sagar Lonial, MD
Speaker invited
Shaji Kumar, MD

2:35 pm
Coffee break

2:55 pm
CML Session
Debate: What is the best tyrosine kinase inhibitor for frontline therapy of CML?
Gail J. Roboz, MD
Hagop M. Kantarjian, MD

3:25 pm
Debate: What is the most appropriate salvage therapy for post-imatinib failure in CML?
Jorge E. Cortes, MD
Stephen Nimer, MD

3:55 pm
Evolving and promising therapeutic strategies for post-TKI failure in CML
Hagop M. Kantarjian, MD

4:20 pm
Adjourn

Saturday, May 1, 2010

8:05 am
CLL Session
Debate: FCR is the best frontline therapy for CLL patient ≥65 years of age
Susan O’Brien, MD
Asher Chanan-Khan, MD

8:30 am
Debate: How prominent should the roles of lenalidomide, bendamustine and ofatumumab be in the frontline therapy of CLL?
Susan O’Brien, MD
Asher A. Chanan-Khan, MD

8:55 am
Myeloproliferative neoplasm session
Moderator: Richard T. Silver, MD

How I deal with the difficult questions in the management of Essential Thrombocythemia
Ruben A. Mesa, MD

9:25 am
What is the role of allogeneic transplantation in myeloproliferative neoplasms
Jorge E. Cortes, MD
Ruben A. Mesa, MD

9:50 am
Coffee break

10:10 am
Myeloma Session II
How I manage multiple myeloma patients who present with significant pre-existing illnesses or serious complications of the myeloma:
Rafael Fonseca, MD
Shaji Kumar, MD
S. Vincent Rajkumar, MD

10:50 am
Debate: For newly diagnosed multiple myeloma patients who relapse from a ≥VGPR response more than 12 months following
frontline therapy, what is the best salvage strategy?
Robert Z. Orlowski, MD, PhD
Rafael Fonseca, MD

11:15 am
The next great therapeutic challenge in multiple myeloma: Designing novel agents and combinations to overcome myeloma
cell resistance to proteasome and immunomodulatory agents
Speaker invited

11:40 am
Debate: Do nucleoside analogues still have a role in the frontline therapy of symptomatic Waldenstroms Macroglobulinemia?
Shaji Kumar, MD
Steven P. Treon, MD, PhD

12:10 pm
Lunch

1:10 pm
Lymphoma Session II
Emerging and promising novel agents for B-cell and T-cell lymphomas
Owen A. O’Connor, MD, PhD

1:40 pm
Debate: Should treatment for limited stage non-bulky hodgkins lymphoma include radiation therapy?
Peter Martin, MD
Morton Coleman, MD, FACP

2:05 pm
Coffee break

2:25 pm
MDS Session
Moderator: Richard T. Silver, MD

Debate: What is the best therapy for MDS patients with deletion 5q?
Gail J. Roboz, MD
Guillermo Garcia-Manero, MD

2:50 pm
Debate: What is the best frontline therapy for intermediate-2 and high risk MDS?
Gail J. Roboz, MD
Jorge E. Cortes, MD

3:15 pm
Novel and evolving therapeutic strategies for MDS
Guillermo Garcia-Manero, MD

3:40 pm
Summary

3:50 pm
Adjourn

Information coming soon.

Registration Fees

Regular........................................$150.00
If payment received by April 22, 2010

Full/Onsite...................................$250.00
If payment received by April 22, 2010

Nurses/Residents/Students*.....$75.00
*proof of eligibility must accompany registration

Registration Procedures

To Register: You may register online by April 22, 2010 at www.imedex.com, by calling Imedex at +1 (678) 242 0906 or by returning the registration form in this program by mail or fax. If you mail the form, please keep a copy for your records. Registration confirmations will be issued before the meeting.

To qualify for special registration fees, registration and full payment must be received by Imedex by the dates specified.

Payment: To pre-register, registration and payment must be received no later than April 22, 2010. Please register onsite
after this date. Contact Imedex at +1 (678) 242 0906 or visit our website at www.imedex.com to ensure the course is
being held as scheduled and to confirm that the meeting is not full. Registration fees must be remitted by credit card or
check. Checks should be payable to Imedex. Attendee is not registered until full payment is received.

Registration Fee Inclusions:Registration fees include admittance to all scientific sessions, conference materials, processing of certificates of attendance or continuing medical education, and all event functions as specified in the agenda.

Cancellation: For registration fees to be refunded, written notice of cancellation must be received at meetings@imedex.com no later than April 22, 2010. The amount of registration fees remitted, minus a $75 administrative charge, will be refunded after the conference. Substitutions are accepted with written notification. No refunds will be made if notice is received after April 22, 2010.

Imedex does not accept responsibility for covering travel, accommodation or any other costs incurred by registrants in the rare event that this meeting should be canceled for any reason. Every effort will be made to give reasonable notice in the event of cancellation. The event agenda is subject to change without notice.

The Westin New York at Times Square
270 West 43rd Street
New York, New York 10036
Tel.: +1 (212) 201 2700
Fax: +1 (212) 201 2701
www.westinny.com

The fragrant aroma of White Tea welcomes you upon arrival at The Westin New York at Times Square. Discover 863 rooms and suites with a soothing color palette and views of New York City and the Hudson River. Utilize such modern amenities as high-speed internet access with wireless connectivity available in select rooms. Note the personal touches, like the custom-designed terry bathrobe. Experience a rejuvenated transformation when you awake in Westin’s Heavenly Bed® or step from
Westin’s Heavenly Bath^®.

For the convenience of attendees, a limited number of rooms have been reserved until April 8, 2010 at a discounted rate of $229 single/double occupancy, plus tax, currently at 14.75%. This rate is not guaranteed outside the conference dates or after April 8, 2010.

To reserve your room please contact the Westin New York at Times Square reservations department at (212) 201 2700 or visit the hotel’s website at www.westinny.com. To receive the group rate, callers must identify themselves as being with the Great Debates and Updates in Hematologic Malignancies group. Reservation requests received after April 8, 2010 may not be guaranteed the group rate.

Dear Colleagues,

It is with great pleasure and enthusiasm that we invite you to attend Great Debates and Updates in Hematologic Malignancies, taking place April 30 – May 1, 2010 in New York, New York.Covering the broad continuum of hematologic malignancies, from lymphoma to leukemia to myeloma to myeloproliferative disorders, this one-of-a-kind hematology conference has a broad appeal to attendees and provides the most substantial curriculum. Using a combination of didactic presentations, as well as discussions in areas of controversy in hematology, the highly-informative “debate” format is one that you will find both
enjoyable and educational.

Attendees will have the chance to interact with nationally-recognized thought leaders who will take opposing positions on topics of interest and provide you with an insightful look at more than one side of a question.Discussions will focus on how the new data fits into the current community practice of hematology, and will be aimed at facilitating rapid incorporation of important new advances in treatment into your current practice.

For any healthcare professional interested and/or involved in the management and treatment of patients with hematologic malignancies, this conference is one that you will not want to miss! We look forward to seeing you in New York for what promises to be a rewarding professional update!

Sincerely,
Hagop Kantarjian, MD
John P. Leonard, MD
Robert Z. Orlowski, MD, PhD

ORGANIZER

Imedex
4325 Alexander Drive
Alpharetta, GA 30022-3740 USA
Tel.: +1 (770) 751 7332
Fax: +1 (770) 751 7334
Email: meetings@imedex.com
Web: www.imedex.com

Imedex is a brand and assumed name used by Imedex, LLC (hereby referred to as Imedex). Imedex is solely responsible for this agenda’s content. Although Imedex attempts to ensure that the information in our program is accurate and timely, matters and opinions discussed and/or presented with respect to clinical matters are those of the discussion participants only, and not necessarily those of Imedex. Moreover, although Imedex attempts to identify and integrate the most qualified medical professionals in our program, TO THE FULLEST EXTENT PERMITTED BY LAW, IMEDEX EXPRESSLY DISCLAIM ALL WARRANTIES, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING BUT NOT LIMITED TO THE IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OF THIRD PARTIES’ RIGHTS, AND FITNESS FOR A PARTICULAR PURPOSE, WITH RESPECT TO THE CONTENT PRESENTED. IMEDEX FURTHER MAKES NO REPRESENTATIONS OR WARRANTIES ABOUT THE ACCURACY, RELIABILITY, COMPLETENESS OR TIMELINESS OF THE CONTENT OR ANY MATERIAL PRESENTED.

In addition, the material presented and related discussions are not intended to be medical advice, and the presentation or discussion of such material is not intended to create and does not establish a physician-patient relationship. Medical advice of any nature should be sought from an individual’s own physician.

Neither Imedex nor any of its subsidiaries or affiliates is affiliated with or formally endorsed by a medical society.

The following companies have provided an educational grant in support of this conference:

GOLD

Genentech BioOncology
and Biogen Idec

SILVER

BRONZE

Celegene

Several options are available to companies interested in supporting this conference. For more information, please contact Imedex at +1(770) 751 7332, or by email at cme@imedex.com.

The following companies is an exhibitor at this conference: